

Michio Hirano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5779650/publications.pdf>

Version: 2024-02-01

229
papers

19,655
citations

7096

78
h-index

12272

133
g-index

258
all docs

258
docs citations

258
times ranked

17167
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondrial diseases. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16080.	30.5	1,001
2	Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). <i>Nature</i> , 2000, 406, 906-910.	27.8	865
3	Thymidine Phosphorylase Gene Mutations in MNGIE, a Human Mitochondrial Disorder. <i>Science</i> , 1999, 283, 689-692.	12.6	827
4	Human mitochondrial DNA: roles of inherited and somatic mutations. <i>Nature Reviews Genetics</i> , 2012, 13, 878-890.	16.3	620
5	Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. <i>Nature Genetics</i> , 1999, 23, 333-337.	21.4	556
6	Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. <i>Genetics in Medicine</i> , 2015, 17, 689-701.	2.4	414
7	Leigh Syndrome with Nephropathy and CoQ10 Deficiency Due to decaprenyl diphosphate synthase subunit 2 (PDSS2) Mutations. <i>American Journal of Human Genetics</i> , 2006, 79, 1125-1129.	6.2	359
8	FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. <i>Lancet Neurology</i> , The, 2011, 10, 806-818.	10.2	352
9	Topical Review: Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Strokelike Episodes (MELAS): Current Concepts. <i>Journal of Child Neurology</i> , 1994, 9, 4-13.	1.4	351
10	MELAS: An original case and clinical criteria for diagnosis. <i>Neuromuscular Disorders</i> , 1992, 2, 125-135.	0.6	330
11	Mitochondrial neurogastrointestinal encephalomyopathy: An autosomal recessive disorder due to thymidine phosphorylase mutations. <i>Annals of Neurology</i> , 2000, 47, 792-800.	5.3	324
12	A Mutation in Para-Hydroxybenzoate-Polyprenyl Transferase (COQ2) Causes Primary Coenzyme Q10 Deficiency. <i>American Journal of Human Genetics</i> , 2006, 78, 345-349.	6.2	322
13	The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. <i>Brain</i> , 2007, 130, 2037-2044.	7.6	298
14	The clinical maze of mitochondrial neurology. <i>Nature Reviews Neurology</i> , 2013, 9, 429-444.	10.1	293
15	ADCK3, an Ancestral Kinase, Is Mutated in a Form of Recessive Ataxia Associated with Coenzyme Q10 Deficiency. <i>American Journal of Human Genetics</i> , 2008, 82, 661-672.	6.2	290
16	Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 19126-19131.	7.1	273
17	Novel cell lines derived from adult human ventricular cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2005, 39, 133-147.	1.9	236
18	Nuclear genome transfer in human oocytes eliminates mitochondrial DNA variants. <i>Nature</i> , 2013, 493, 632-637.	27.8	223

#	ARTICLE	IF	CITATIONS
19	Atypical clinical presentations associated with the MELAS mutation at position 3243 of human mitochondrial DNA. <i>Neuromuscular Disorders</i> , 1993, 3, 43-50.	0.6	219
20	Altered Thymidine Metabolism Due to Defects of Thymidine Phosphorylase. <i>Journal of Biological Chemistry</i> , 2002, 277, 4128-4133.	3.4	209
21	A Nonsense Mutation in COQ9 Causes Autosomal-Recessive Neonatal-Onset Primary Coenzyme Q10 Deficiency: A Potentially Treatable Form of Mitochondrial Disease. <i>American Journal of Human Genetics</i> , 2009, 84, 558-566.	6.2	206
22	GD3 ganglioside is a glycolipid characteristic of immature neuroectodermal cells. <i>Journal of Neuroimmunology</i> , 1984, 7, 179-192.	2.3	193
23	Heterogeneity of Coenzyme Q ₁₀ Deficiency. <i>Archives of Neurology</i> , 2012, 69, 978-83.	4.5	192
24	Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. <i>Brain</i> , 2011, 134, 3326-3332.	7.6	191
25	Genetic Drift Can Compromise Mitochondrial Replacement by Nuclear Transfer in Human Oocytes. <i>Cell Stem Cell</i> , 2016, 18, 749-754.	11.1	170
26	Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. <i>Journal of Clinical Investigation</i> , 2003, 111, 1913-1921.	8.2	165
27	Human Coenzyme Q10 Deficiency. <i>Neurochemical Research</i> , 2007, 32, 723-727.	3.3	163
28	A homoplasmic mitochondrial transfer Ribonucleic Acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1786-1796.	2.8	161
29	Navajo Neurohepatopathy Is Caused by a Mutation in the MPV17 Gene. <i>American Journal of Human Genetics</i> , 2006, 79, 544-548.	6.2	158
30	Coenzyme Q and mitochondrial disease. <i>Developmental Disabilities Research Reviews</i> , 2010, 16, 183-188.	2.9	157
31	New treatments for mitochondrial disease—no time to drop our standards. <i>Nature Reviews Neurology</i> , 2013, 9, 474-481.	10.1	157
32	Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE): A Disease of Two Genomes. <i>Neurologist</i> , 2004, 10, 8-17.	0.7	156
33	Mitochondrial DNA depletion and <i>dGK</i> gene mutations. <i>Annals of Neurology</i> , 2002, 52, 311-317.	5.3	152
34	Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ ₁₀ deficiency. <i>FASEB Journal</i> , 2008, 22, 1874-1885.	0.5	150
35	Recurrent De Novo and Biallelic Variation of ATAD3A, Encoding a Mitochondrial Membrane Protein, Results in Distinct Neurological Syndromes. <i>American Journal of Human Genetics</i> , 2016, 99, 831-845.	6.2	146
36	Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ ₁₀ deficiency. <i>FASEB Journal</i> , 2010, 24, 3733-3743.	0.5	142

#	ARTICLE	IF	CITATIONS
37	Apparent mtDNA heteroplasmy in Alzheimer's disease patients and in normals due to PCR amplification of nucleus-embedded mtDNA pseudogenes. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14894-14899.	7.1	137
38	Mitochondria in neuromuscular disorders1This paper is dedicated to the memory of Giovanni Salviati, a great scientist and a dear friend.1. Biochimica Et Biophysica Acta - Bioenergetics, 1998, 1366, 199-210.	1.0	136
39	<i>POLG</i> mutations and Alpers syndrome. Annals of Neurology, 2005, 57, 921-923.	5.3	131
40	Mitochondrial encephalomyopathies: an update. Neuromuscular Disorders, 2005, 15, 276-286.	0.6	130
41	Approaches to the treatment of mitochondrial diseases. Muscle and Nerve, 2006, 34, 265-283.	2.2	130
42	Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. Human Molecular Genetics, 2007, 16, 1091-1097.	2.9	129
43	A Diagnostic Algorithm for Metabolic Myopathies. Current Neurology and Neuroscience Reports, 2010, 10, 118-126.	4.2	128
44	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015, 138, 2847-2858.	7.6	128
45	Does Linezolid Cause Lactic Acidosis by Inhibiting Mitochondrial Protein Synthesis?. Clinical Infectious Diseases, 2005, 40, e113-e116.	5.8	123
46	Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. Human Molecular Genetics, 2009, 18, 714-722.	2.9	123
47	ETFDH mutations, CoQ10 levels, and respiratory chain activities in patients with riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency. Neuromuscular Disorders, 2009, 19, 212-216.	0.6	118
48	The G13513A Mutation in the ND5 Gene of Mitochondrial DNA as a Common Cause of MELAS or Leigh Syndrome. Archives of Neurology, 2008, 65, 368-72.	4.5	113
49	Emerging therapies for mitochondrial diseases. Essays in Biochemistry, 2018, 62, 467-481.	4.7	113
50	Glycogen branching enzyme deficiency in adult polyglucosan body disease. Annals of Neurology, 1993, 33, 88-93.	5.3	112
51	Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. Brain, 2009, 132, 3165-3174.	7.6	112
52	Human CoQ₁₀ deficiencies. BioFactors, 2008, 32, 113-118.	5.4	110
53	X-Linked Dominant Scapulooperoneal Myopathy Is Due to a Mutation in the Gene Encoding Four-and-a-Half-LIM Protein 1. American Journal of Human Genetics, 2008, 82, 208-213.	6.2	108
54	Maternally Inherited Cardiomyopathy: An Atypical Presentation of the mtDNA 12S rRNA Gene A1555G Mutation. American Journal of Human Genetics, 1999, 64, 295-300.	6.2	107

#	ARTICLE	IF	CITATIONS
55	Definitive Diagnosis of Mitochondrial Neurogastrointestinal Encephalomyopathy by Biochemical Assays. <i>Clinical Chemistry</i> , 2004, 50, 120-124.	3.2	107
56	Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. <i>Seminars in Cell and Developmental Biology</i> , 2001, 12, 417-427.	5.0	105
57	Clinical and Genetic Heterogeneity in Progressive External Ophthalmoplegia Due to Mutations in Polymerase β . <i>Archives of Neurology</i> , 2003, 60, 1279-84.	4.5	104
58	A functionally dominant mitochondrial DNA mutation. <i>Human Molecular Genetics</i> , 2008, 17, 1814-1820.	2.9	104
59	Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. <i>Human Molecular Genetics</i> , 2008, 17, 2433-2440.	2.9	101
60	Gastrointestinal Dysmotility in Mitochondrial Neurogastrointestinal Encephalomyopathy Is Caused by Mitochondrial DNA Depletion. <i>American Journal of Pathology</i> , 2008, 173, 1120-1128.	3.8	100
61	Therapeutic prospects for mitochondrial disease. <i>Trends in Molecular Medicine</i> , 2010, 16, 268-276.	6.7	97
62	Mitochondrial encephalomyopathies: Clinical and molecular analysis. <i>Journal of Bioenergetics and Biomembranes</i> , 1994, 26, 291-299.	2.3	96
63	Primary and secondary CoQ ₁₀ deficiencies in humans. <i>BioFactors</i> , 2011, 37, 361-365.	5.4	96
64	Haploinsufficiency of <i>COQ4</i> causes coenzyme Q ₁₀ deficiency. <i>Journal of Medical Genetics</i> , 2012, 49, 187-191.	3.2	95
65	Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	95
66	Treatment of CoQ10 Deficient Fibroblasts with Ubiquinone, CoQ Analogs, and Vitamin C: Time- and Compound-Dependent Effects. <i>PLoS ONE</i> , 2010, 5, e11897.	2.5	92
67	Diagnostic odyssey of patients with mitochondrial disease. <i>Neurology: Genetics</i> , 2018, 4, e230.	1.9	92
68	Mitochondrial Neurogastrointestinal Encephalomyopathy Syndrome Maps to Chromosome 22q13.32-qter. <i>American Journal of Human Genetics</i> , 1998, 63, 526-533.	6.2	91
69	Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency. <i>Biochemical and Biophysical Research Communications</i> , 2003, 303, 14-18.	2.1	91
70	Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2 Deficiency. <i>Annals of Neurology</i> , 2017, 81, 641-652.	5.3	89
71	Mutations in coenzyme Q10 biosynthetic genes. <i>Journal of Clinical Investigation</i> , 2007, 117, 587-589.	8.2	89
72	ND5 is a hot-spot for multiple atypical mitochondrial DNA deletions in mitochondrial neurogastrointestinal encephalomyopathy. <i>Human Molecular Genetics</i> , 2003, 13, 91-101.	2.9	88

#	ARTICLE	IF	CITATIONS
73	Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. <i>Neuromuscular Disorders</i> , 2008, 18, 453-459.	0.6	87
74	Maintenance of Human Rearranged Mitochondrial DNAs in Long-Term Cultured Transmitochondrial Cell Lines. <i>Molecular Biology of the Cell</i> , 2000, 11, 2349-2358.	2.1	85
75	Jumping Performance of Frogs (<i>Rana Pipiens</i>) as a Function of Muscle Temperature. <i>Journal of Experimental Biology</i> , 1984, 108, 429-439.	1.7	85
76	A <i>POGLUT1</i> mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss. <i>EMBO Molecular Medicine</i> , 2016, 8, 1289-1309.	6.9	84
77	CoQ10 deficiencies and MNGIE: Two treatable mitochondrial disorders. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 625-631.	2.4	83
78	Inhibition of NADPH oxidase 2 (NOX2) prevents sepsis-induced cardiomyopathy by improving calcium handling and mitochondrial function. <i>JCI Insight</i> , 2017, 2, .	5.0	83
79	Autophagic Vacuoles with Sarcolemmal Features Delineate Danon Disease and Related Myopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 513-522.	1.7	81
80	Senataxin mutations and amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 223-227.	2.1	81
81	Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. <i>EMBO Molecular Medicine</i> , 2014, 6, 1016-1027.	6.9	79
82	Inhibition of NADPH Oxidase 2 (NOX2) Prevents Oxidative Stress and Mitochondrial Abnormalities Caused by Saturated Fat in Cardiomyocytes. <i>PLoS ONE</i> , 2016, 11, e0145750.	2.5	78
83	Identical Mitochondrial DNA Deletion in a Woman with Ocular Myopathy and in Her Son with Pearson Syndrome. <i>American Journal of Human Genetics</i> , 2002, 71, 679-683.	6.2	76
84	Mitochondrial DNA and RNA processing in MELAS. <i>Annals of Neurology</i> , 1996, 40, 172-180.	5.3	74
85	Clinical and genetic analysis of lipid storage myopathies. <i>Muscle and Nerve</i> , 2009, 39, 333-342.	2.2	74
86	Retrospective natural history of thymidine kinase 2 deficiency. <i>Journal of Medical Genetics</i> , 2018, 55, 515-521.	3.2	73
87	Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy. <i>Annals of Neurology</i> , 2019, 86, 293-303.	5.3	72
88	Natural underlying mtDNA heteroplasmy as a potential source of intra-personal PSC variability. <i>EMBO Journal</i> , 2016, 35, 1979-1990.	7.8	71
89	Low-dose rapamycin extends lifespan in a mouse model of mtDNA depletion syndrome. <i>Human Molecular Genetics</i> , 2017, 26, 4588-4605.	2.9	70
90	Mitochondrial DNA Depletion and Thymidine Phosphate Pool Dynamics in a Cellular Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. <i>Journal of Biological Chemistry</i> , 2006, 281, 22720-22728.	3.4	68

#	ARTICLE	IF	CITATIONS
91	MPV17 Mutations Causing Adult-Onset Multisystemic Disorder With Multiple Mitochondrial DNA Deletions. Archives of Neurology, 2012, 69, 1648.	4.5	68
92	Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome. Human Molecular Genetics, 2014, 23, 2459-2467.	2.9	67
93	MPV17 Loss Causes Deoxynucleotide Insufficiency and Slow DNA Replication in Mitochondria. PLoS Genetics, 2016, 12, e1005779.	3.5	67
94	Mitochondria and the heart. Current Opinion in Cardiology, 2001, 16, 201-210.	1.8	65
95	Association of myopathy with large-scale mitochondrial dna duplications and deletions: Which is pathogenic?. Annals of Neurology, 1997, 42, 180-188.	5.3	64
96	MNGIE: from nuclear DNA to mitochondrial DNA. Neuromuscular Disorders, 2001, 11, 7-10.	0.6	64
97	Late-onset MNGIE due to partial loss of thymidine phosphorylase activity. Annals of Neurology, 2005, 58, 649-652.	5.3	64
98	Thymidine and deoxyuridine accumulate in tissues of patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). FEBS Letters, 2007, 581, 3410-3414.	2.8	64
99	Mitochondrial Neurogastrointestinal Encephalomyopathy: Evidence of Mitochondrial DNA Depletion in the Small Intestine. Gastroenterology, 2006, 130, 893-901.	1.3	63
100	Tissue-specific oxidative stress and loss of mitochondria in CoQ10-deficient <i>Pdss2</i> mutant mice. FASEB Journal, 2013, 27, 612-621.	0.5	61
101	Three-Dimensional Analysis of Mitochondrial Crista Ultrastructure in a Patient with Leigh Syndrome by In Situ Cryoelectron Tomography. IScience, 2018, 6, 83-91.	4.1	60
102	Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene. Neuromuscular Disorders, 2010, 20, 397-402.	0.6	58
103	International Workshop:. Neuromuscular Disorders, 2017, 27, 1126-1137.	0.6	58
104	Mitochondrial Myopathy of Childhood Associated With Mitochondrial DNA Depletion and a Homozygous Mutation (T77M) in the TK2 Gene. Archives of Neurology, 2003, 60, 1007.	4.5	57
105	Gene Therapy Using a Liver-targeted AAV Vector Restores Nucleoside and Nucleotide Homeostasis in a Murine Model of MNGIE. Molecular Therapy, 2014, 22, 901-907.	8.2	55
106	Protean Phenotypic Features of the A3243G Mitochondrial DNA Mutation. Archives of Neurology, 2009, 66, 85-91.	4.5	53
107	The <i>COQ2</i> genotype predicts the severity of coenzyme Q10 deficiency. Human Molecular Genetics, 2016, 25, 4256-4265.	2.9	53
108	A novel mitochondrial tRNA ^{Leu} (UUR) mutation in a patient with features of MERRF and Kearns-Sayre syndrome. Neuromuscular Disorders, 2003, 13, 334-340.	0.6	51

#	ARTICLE	IF	CITATIONS
109	Defects of Intergenomic Communication: <i>Where Do We Stand?</i> . <i>Brain Pathology</i> , 2000, 10, 451-461.	4.1	50
110	Primary coenzyme Q ₁₀ deficiency and the brain. <i>BioFactors</i> , 2003, 18, 145-152.	5.4	49
111	Thymidine phosphorylase mutations cause instability of mitochondrial DNA. <i>Gene</i> , 2005, 354, 152-156.	2.2	49
112	Functional characterization of human COQ4, a gene required for Coenzyme Q10 biosynthesis. <i>Biochemical and Biophysical Research Communications</i> , 2008, 372, 35-39.	2.1	49
113	Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the <scp>MNGIE</scp> International Network. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 376-387.	3.6	47
114	USMG5 Ashkenazi Jewish founder mutation impairs mitochondrial complex V dimerization and ATP synthesis. <i>Human Molecular Genetics</i> , 2018, 27, 3305-3312.	2.9	45
115	Branching Enzyme Deficiency. <i>JAMA Neurology</i> , 2014, 71, 41.	9.0	43
116	Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. <i>Molecular Genetics and Metabolism</i> , 2016, 119, 187-206.	1.1	41
117	Effects of Inhibiting CoQ10 Biosynthesis with 4-nitrobenzoate in Human Fibroblasts. <i>PLoS ONE</i> , 2012, 7, e30606.	2.5	40
118	Long-Term Sustained Effect of Liver-Targeted Adeno-Associated Virus Gene Therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy. <i>Human Gene Therapy</i> , 2018, 29, 708-718.	2.7	39
119	Clinical Presentations of Coenzyme Q10 Deficiency Syndrome. <i>Molecular Syndromology</i> , 2014, 5, 141-146.	0.8	38
120	Mitochondrial diseases in North America. <i>Neurology: Genetics</i> , 2020, 6, e402.	1.9	38
121	MRI of Five Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy. <i>American Journal of Roentgenology</i> , 2004, 182, 1537-1541.	2.2	37
122	Thymidine Phosphorylase Participates in Platelet Signaling and Promotes Thrombosis. <i>Circulation Research</i> , 2014, 115, 997-1006.	4.5	37
123	Human aging DNA methylation signatures are conserved but accelerated in cultured fibroblasts. <i>Epigenetics</i> , 2019, 14, 961-976.	2.7	36
124	SETX (senataxin), the helicase mutated in AOA2 and ALS4, functions in autophagy regulation. <i>Autophagy</i> , 2021, 17, 1889-1906.	9.1	34
125	Characterization of Danon disease in a male patient and his affected mother. <i>Neuromuscular Disorders</i> , 2003, 13, 708-711.	0.6	33
126	Advances in primary mitochondrial myopathies. <i>Current Opinion in Neurology</i> , 2019, 32, 715-721.	3.6	32

#	ARTICLE	IF	CITATIONS
127	Intracellular calcium leak as a therapeutic target for RYR1-related myopathies. <i>Acta Neuropathologica</i> , 2020, 139, 1089-1104.	7.7	32
128	Pathogenesis and Treatment of Mitochondrial Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2009, 652, 139-170.	1.6	31
129	Pathogenesis of the deafness-associated A1555G mitochondrial DNA mutation. <i>Biochemical and Biophysical Research Communications</i> , 2002, 293, 521-529.	2.1	30
130	Onset and organ specificity of Tk2 deficiency depends on Tk1 down-regulation and transcriptional compensation. <i>Human Molecular Genetics</i> , 2011, 20, 155-164.	2.9	30
131	The clinical spectrum of the congenital myasthenic syndrome resulting from COL13A1 mutations. <i>Brain</i> , 2019, 142, 1547-1560.	7.6	30
132	Mitochondrial diseases. <i>Neurologic Clinics</i> , 2002, 20, 809-839.	1.8	29
133	A novel complex neurological phenotype due to a homozygous mutation in FDX2. <i>Brain</i> , 2018, 141, 2289-2298.	7.6	29
134	Late-onset thymidine kinase 2 deficiency: a review of 18 cases. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 100.	2.7	29
135	Epidemic optic and peripheral neuropathy in Cuba: A unique geopolitical public health problem. <i>Survey of Ophthalmology</i> , 1997, 41, 341-353.	4.0	28
136	Amyotrophic Lateral Sclerosis With Ragged-Red Fibers. <i>Archives of Neurology</i> , 2008, 65, 403-6.	4.5	28
137	<i>TK2</i> mutation presenting as indolent myopathy. <i>Neurology</i> , 2013, 80, 504-506.	1.1	28
138	Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. <i>Human Gene Therapy</i> , 2016, 27, 656-667.	2.7	26
139	Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). <i>Molecular Genetics and Metabolism</i> , 2020, 130, 58-64.	1.1	26
140	Metabolic shift underlies recovery in reversible infantile respiratory chain deficiency. <i>EMBO Journal</i> , 2020, 39, e105364.	7.8	26
141	Alteration of Nucleotide Metabolism: A New Mechanism for Mitochondrial Disorders. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 845-51.	2.3	25
142	Dystonia-Ataxia with early handwriting deterioration in COQ8A mutation carriers: A case series and literature review. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 8-16.	2.2	25
143	Mitochondrial disease patients' perception of dietary supplements' use. <i>Molecular Genetics and Metabolism</i> , 2016, 119, 100-108.	1.1	24
144	MERRF and Kearns-Sayre overlap syndrome due to the mitochondrial DNA m.3291T>C mutation. <i>Muscle and Nerve</i> , 2011, 44, 448-451.	2.2	23

#	ARTICLE	IF	CITATIONS
145	Pathomechanisms in Coenzyme Q₁₀-Deficient Human Fibroblasts. <i>Molecular Syndromology</i> , 2014, 5, 163-169.	0.8	23
146	Leber's hereditary optic neuropathy mitochondrial DNA mutations in normal-tension glaucoma. <i>Graefes's Archive for Clinical and Experimental Ophthalmology</i> , 2001, 239, 437-440.	1.9	22
147	Human mitochondrial pyrophosphatase: cDNA cloning and analysis of the gene in patients with mtDNA depletion syndromes. <i>Genomics</i> , 2006, 87, 410-416.	2.9	22
148	<sc><i>GGPS1</i></sc> Mutations Cause Muscular Dystrophy/Hearing Loss/Ovarian Insufficiency Syndrome. <i>Annals of Neurology</i> , 2020, 88, 332-347.	5.3	22
149	A novel ECGF1 mutation in a Thai patient with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 613-616.	1.4	21
150	Coenzyme Q10 Deficiencies in Neuromuscular Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2009, 652, 117-128.	1.6	21
151	Detection of uniparental isodisomy in autosomal recessive mitochondrial DNA depletion syndrome by high-density SNP array analysis. <i>Journal of Human Genetics</i> , 2011, 56, 834-839.	2.3	21
152	Whole exome sequencing identifies a homozygous POLG2 missense variant in an infant with fulminant hepatic failure and mitochondrial DNA depletion. <i>European Journal of Medical Genetics</i> , 2016, 59, 540-545.	1.3	21
153	A novel thymidine phosphorylase mutation in a Spanish MNGIE patient. <i>Journal of the Neurological Sciences</i> , 2005, 228, 35-39.	0.6	20
154	A polymorphic polymerase. <i>Brain</i> , 2006, 129, 1637-1639.	7.6	20
155	A novel tRNA ^{Val} mitochondrial DNA mutation causing MELAS. <i>Journal of the Neurological Sciences</i> , 2008, 270, 23-27.	0.6	20
156	Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy. <i>Scientific Reports</i> , 2020, 10, 10111.	3.3	20
157	Survival transcriptome in the coenzyme Q₁₀ deficiency syndrome is acquired by epigenetic modifications: a modelling study for human coenzyme Q₁₀ deficiencies. <i>BMJ Open</i> , 2013, 3, e002524.	1.9	19
158	Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neurogastrointestinal encephalopathy. <i>Brain</i> , 2014, 137, 1337-1349.	7.6	19
159	A Novel Mutation in PNPLA2 Leading to Neutral Lipid Storage Disease With Myopathy. <i>Archives of Neurology</i> , 2012, 69, 1190.	4.5	18
160	Cerebral Mitochondrial Microangiopathy Leads to Leukoencephalopathy in Mitochondrial Neurogastrointestinal Encephalopathy. <i>American Journal of Neuroradiology</i> , 2018, 39, 427-434.	2.4	18
161	Fatigue in primary genetic mitochondrial disease: No rest for the weary. <i>Neuromuscular Disorders</i> , 2019, 29, 895-902.	0.6	18
162	Leber's Hereditary Optic Neuropathy Mitochondrial DNA Mutations at Nucleotides 11778 and 3460 in Multiple Sclerosis. <i>Ophthalmologica</i> , 1999, 213, 171-175.	1.9	17

#	ARTICLE	IF	CITATIONS
163	Analysis of mtDNA deletions in muscle by in situ hybridization. <i>Muscle and Nerve</i> , 2000, 23, 80-85.	2.2	17
164	Selective muscle fiber loss and molecular compensation in mitochondrial myopathy due to TK2 deficiency. <i>Journal of the Neurological Sciences</i> , 2008, 267, 137-141.	0.6	17
165	Thymidine Kinase 2 Deficiency-Induced Mitochondrial DNA Depletion Causes Abnormal Development of Adipose Tissues and Adipokine Levels in Mice. <i>PLoS ONE</i> , 2011, 6, e29691.	2.5	17
166	Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy. <i>Human Reproduction</i> , 2016, 31, 1058-1065.	0.9	17
167	Bioavailability and cytosolic kinases modulate response to deoxynucleoside therapy in TK2 deficiency. <i>EBioMedicine</i> , 2019, 46, 356-367.	6.1	17
168	Leber hereditary optic neuropathy plus dystonia, and transverse myelitis due to double mutations in MT-ND4 and MT-ND6. <i>Journal of Neurology</i> , 2020, 267, 823-829.	3.6	17
169	Cytochrome oxidase deficiency: progress and problems. , 1994, , 91-115.		16
170	Paracrine Stimulation of Endothelial Cell Motility and Angiogenesis by Platelet-Derived Deoxyribose-1-Phosphate. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2631-2638.	2.4	16
171	Cardiac transplantation in Friedreich Ataxia: Extended follow-up. <i>Journal of the Neurological Sciences</i> , 2017, 375, 471-473.	0.6	16
172	Alpha-1-Antitrypsin Promoter Improves the Efficacy of an Adeno-Associated Virus Vector for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy. <i>Human Gene Therapy</i> , 2019, 30, 985-998.	2.7	16
173	Disentangling (Epi)Genetic and Environmental Contributions to the Mitochondrial 3243A>G Mutation Phenotype. <i>JAMA Neurology</i> , 2016, 73, 923.	9.0	15
174	A Novel SUCLA2 Mutation Presenting as a Complex Childhood Movement Disorder. <i>Journal of Child Neurology</i> , 2017, 32, 246-250.	1.4	15
175	Oculopharyngeal muscular dystrophy, other ocular myopathies, and progressive external ophthalmoplegia. <i>Neuromuscular Disorders</i> , 1997, 7, S15-S21.	0.6	14
176	Assessment of Thymidine Phosphorylase Function: Measurement of Plasma Thymidine (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 222 T	0.9	14
177	Synergistic Deoxynucleoside and Gene Therapies for Thymidine Kinase 2 Deficiency. <i>Annals of Neurology</i> , 2021, 90, 640-652.	5.3	14
178	Thymidine Phosphorylase Gene Mutations Cause Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). <i>Internal Medicine</i> , 2006, 45, 1103-1103.	0.7	12
179	Recurrent myoglobinuria in a sporadic patient with a novel mitochondrial DNA tRNAIle mutation. <i>Journal of the Neurological Sciences</i> , 2011, 303, 39-42.	0.6	12
180	Measurement of Mitochondrial dNTP Pools. <i>Methods in Molecular Biology</i> , 2012, 837, 135-148.	0.9	12

#	ARTICLE	IF	CITATIONS
181	Characterization of the human homozygous R182W POLG2 mutation in mitochondrial DNA depletion syndrome. <i>PLoS ONE</i> , 2018, 13, e0203198.	2.5	11
182	Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosides. <i>EBioMedicine</i> , 2020, 62, 103133.	6.1	11
183	Mitochondrial neurogastrointestinal encephalomyopathy and thymidine metabolism: results and hypotheses. <i>Mitochondrion</i> , 2002, 2, 143-147.	3.4	10
184	Altered gene transcription profiles in fibroblasts harboring either TK2 or DGUOK mutations indicate compensatory mechanisms. <i>Experimental Cell Research</i> , 2009, 315, 1429-1438.	2.6	9
185	Autocrine amplification of integrin α IIb β 3 activation and platelet adhesive responses by deoxyribose-1-phosphate. <i>Thrombosis and Haemostasis</i> , 2013, 109, 1108-1119.	3.4	9
186	Cardiomyopathy and altered integrin-actin signaling in Fhl1 mutant female mice. <i>Human Molecular Genetics</i> , 2019, 28, 209-219.	2.9	9
187	Rod-sparing paraneoplastic retinopathy, opsoclonus, and peripheral neuropathy due to small cell lung carcinoma. <i>Neuro-Ophthalmology</i> , 1997, 17, 101-105.	1.0	8
188	Achalasia as the Harbinger of a Novel Mitochondrial Disorder in Childhood. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 40, 512-517.	1.8	8
189	The m.3244C>A mutation in mtDNA is another cause of progressive external ophthalmoplegia. <i>Neuromuscular Disorders</i> , 2009, 19, 297-299.	0.6	8
190	Targeted impairment of thymidine kinase 2 expression in cells induces mitochondrial DNA depletion and reveals molecular mechanisms of compensation of mitochondrial respiratory activity. <i>Biochemical and Biophysical Research Communications</i> , 2011, 407, 333-338.	2.1	8
191	Mitochondrial Cardioencephalomyopathy Due to a Novel SCO2 Mutation in a Brazilian Patient. <i>JAMA Neurology</i> , 2013, 70, 258.	9.0	8
192	Growth differentiation factor-15 as a biomarker of strength and recovery in survivors of acute respiratory failure. <i>Thorax</i> , 2019, 74, 1099-1101.	5.6	7
193	Editing the Mitochondrial Genome. <i>New England Journal of Medicine</i> , 2020, 383, 1489-1491.	27.0	7
194	Advances in Thymidine Kinase 2 Deficiency: Clinical Aspects, Translational Progress, and Emerging Therapies. <i>Journal of Neuromuscular Diseases</i> , 2022, 9, 225-235.	2.6	6
195	RRM1 variants cause a mitochondrial DNA maintenance disorder via impaired de novo nucleotide synthesis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	6
196	MtDNA maintenance and stability genes: MNGIE and mtDNA depletion syndromes. <i>Topics in Current Genetics</i> , 2004, , 177-200.	0.7	5
197	Mutation in an mtDNA Protein-Coding Gene. <i>Journal of Child Neurology</i> , 2013, 28, 264-268.	1.4	5
198	Implications of mitochondrial DNA mutations in human induced pluripotent stem cells. <i>Nature Reviews Genetics</i> , 2022, 23, 69-70.	16.3	5

#	ARTICLE	IF	CITATIONS
199	Leukocyte cytokine responses in adult patients with mitochondrial DNA defects. <i>Journal of Molecular Medicine</i> , 2022, 100, 963-971.	3.9	5
200	Chapter 3 Molecular Genetic Basis of the Mitochondrial Encephalomyopathies. <i>Blue Books of Practical Neurology</i> , 2002, , 69-113.	0.1	4
201	VMA21 Deficiency: A Case of Myocyte Indigestion. <i>Cell</i> , 2009, 137, 213-215.	28.9	4
202	Diagnosis of mitochondrial neurogastrointestinal encephalomyopathy: Proposal of a clinical algorithm. <i>Digestive and Liver Disease</i> , 2014, 46, 664-665.	0.9	4
203	A De Novo Mutation in MTND6 Causes Generalized Dystonia in 2 Unrelated Children. <i>Child Neurology Open</i> , 2016, 3, 2329048X1562793.	1.1	4
204	Mitochondrial Diseases: A Clinical and Molecular History. <i>Pediatric Neurology</i> , 2016, 63, 3-5.	2.1	4
205	Mitochondrial Neurogastrointestinal Encephalomyopathy Disease (MNGIE). , 2019, , 205-222.		4
206	The North American mitochondrial disease registry. , 2020, 4, 81-90.		4
207	Risk mitigation behaviors to prevent infection in the mitochondrial disease community during the COVID-19 pandemic. <i>Molecular Genetics and Metabolism Reports</i> , 2022, 30, 100837.	1.1	4
208	232nd ENMC International Workshop: Recommendations for treatment of mitochondrial DNA maintenance disorders. 16 - 18 June 2017, Heemskerk, The Netherlands.. <i>Neuromuscular Disorders</i> , 2022, , ,	0.6	4
209	Recalcitrant Vomiting, Disturbed Eye Movements, and Leukoencephalopathy. <i>Gastroenterology</i> , 2009, 137, 1581-1861.	1.3	3
210	Stroke-Like Episodes in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). , 2013, , 107-125.		3
211	Collaborative model for diagnosis and treatment of very rare diseases: experience in Spain with thymidine kinase 2 deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 407.	2.7	3
212	Cerebellar Ataxia and Deficiency. , 2013, 1, 1004.		3
213	Vitamin status and mitochondrial DNA mutations in patients with incomplete recovery from an epidemic optic neuropathy in Cuba. <i>Neuro-Ophthalmology</i> , 1996, 16, 355-360.	1.0	2
214	Metabolic Myopathies. , 2007, , 947-956.		2
215	Drug Effects in Patients with Mitochondrial Diseases. , 0, , 311-324.		2
216	Metabolic myopathies. <i>Advances in Neurology</i> , 2002, 88, 217-34.	0.8	2

#	ARTICLE	IF	CITATIONS
217	Does increased superoxide dismutase activity really cause muscular dystrophy?. Annals of Neurology, 1999, 46, 135-135.	5.3	1
218	A First Step in Viral Gene Therapy for Muscular Dystrophy. Current Neurology and Neuroscience Reports, 2010, 10, 71-72.	4.2	1
219	Regulatory environment for novel therapeutic development in mitochondrial diseases. Journal of Inherited Metabolic Disease, 2021, 44, 292-300.	3.6	1
220	Mitochondrial Disorders. , 2008, , 1785-1798.		1
221	Mitochondrial Myopathies. , 2014, , 1335-1353.		1
222	Whole Exome Sequencing detects PYGM variants in two adults with McArdle disease. Journal of Physical Education and Sports Management, 2022, , mcs.a006173.	1.2	1
223	Autosomal dominant hereditary spastic paraplegia with axonal sensory motor polyneuropathy maps to chromosome 21q 22.3. International Journal of Neuroscience, 2016, 126, 1-7.	1.6	0
224	Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE). , 2016, , 199-206.		0
225	Therapies Approaches in Mitochondrial Diseases. , 2021, , 273-305.		0
226	Mitochondrial Disorders. Neurological Disease and Therapy, 2005, , 256-283.	0.0	0
227	Primary Cerebellar CoQ10 Deficiency. , 2016, , 293-297.		0
228	Stroke-Like Episodes in Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). , 2017, , 117-134.		0
229	Visual memory failure presages conversion to <scp>MELAS</scp> phenotype. Annals of Clinical and Translational Neurology, 2022, , .	3.7	0